Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

Masson, Adèle de; Beylot‐Barry, M.; Bouaziz, Jean‐David; Latour, Régis Peffault de; Aubin, F.; Garciaz, Sylvain; D’Incan, M.; Dereure, O.; Dalle, S.; Dompmartin, Anne; Suarez, Félipe; Battistella, Maxime; Vignon‐Pennamen, Marie‐Dominique; Rivet, Jacqueline; Adamski, H.; Brice, Pauline; François, Sylvie; Lissandre, Séverine; Turlure, Pascal; Wierzbicka-Hainaut, E.; Brissot, Éolia; Duléry, Rémy; Servais, Sophie; Ravinet, Aurélie; Tabrizi, Reza; Ingen‐Housz‐Oro, Saskia; Joly, P.; Socié, Gérard; Bagot, Martine; Cellulaire, Société de Greffe de Moëlle et Thérapie Française

doi:10.3324/haematol.2013.098145

Cited by 73 publications

(62 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the case of a CR, ASCT can be performed with the possibility of complete long‐term remission. De Masson et al ., in a French retrospective study of 37 patients with advanced CTCL (two‐thirds had stage IV MF, SS or extracutaneous localization of T‐cell lymphoma), reported the effectiveness of ASCT. In this study, the estimated 2‐year overall survival after ASCT was estimated to be approximately 57% and the progression‐free survival rate was 31% .…”

Section: Discussionmentioning

confidence: 99%

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Mahévas¹,

Ram‐Wolff²,

Battistella

et al. 2019

Br J Dermatol

Self Cite

View full text Add to dashboard Cite

Summary The erythrodermic ulcerated form of mycosis fungoides (MF) is exceptional, and treatment of refractory cases is challenging. Brentuximab vedotin (BV) is a monoclonal antibody combined with monomethyl auristatin E, recently approved for the treatment of refractory CD30+ cutaneous T‐cell lymphoma. We report a case of refractory MF in a 56‐year‐old man with a long history of large‐plaque parapsoriasis, as revealed by psoriasiform erythroderma, treated initially with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) polychemotherapy, inducing a 2‐year complete response. After relapse, interferon and gemcitabine were unsuccessful. Finally, treatment with BV was decided upon, despite the absence of CD30 expression. After three infusions of BV 1·8 mg kg−1, we achieved a complete and stable response, allowing an allogeneic stem cell transplant. The patient is still in complete remission, 19 months after the graft. This case illustrates the possibility of using BV in refractory CD30– MF as a salvage therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Mahévas¹,

Ram‐Wolff²,

Battistella

et al. 2019

Br J Dermatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…A multicenter retrospective analysis of 37 cases of advanced-stage primary CTCLs treated with allogeneic stem cell transplantation included 20 (54%) transformed MF cases. 87 Of these latter cases, there was a 22% transplant-related mortality, 56% relapse or progression, 26% progressionfree survival, and 60% overall survival at 2 years. Previously, success with TSEB and nonmyeloablative (reduced intensity) allogeneic hematopoietic stem-cell transplantation had been reported in a series of 19 patients, 8 of whom had MF with LCT.…”

Section: Allogeneic Stem Cell Transplantmentioning

confidence: 97%

Practical Management of CD30+ Lymphoproliferative Disorders

Hughey

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.

show abstract

“…reported that the 3‐year OS rate in 60 patients with advanced MF/SS who underwent allogeneic HSCT was 54% and that an RIC regimen improved transplant outcome because of less NRM than that in the case of a myeloablative conditioning (MAC) regimen (3‐year OS: 63% vs 29%, 2‐year NRM: 49% vs 14%) . In another retrospective large‐scale study by http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Masson%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24213148 et al ., 2‐year OS was 56%, and 3‐year PFS was 31%, and the type of conditioning regimen (RIC versus MAC) had no significant impact on transplant‐related mortality .…”

Section: Discussionmentioning

confidence: 97%

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

et al. 2014

View full text Add to dashboard Cite

Advanced‐stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced‐intensity conditioning (RIC) regimen, is a promising treatment for advanced‐stage MF/SS. We performed RIC‐HSCT in nine patients with advanced MF/SS. With a median follow‐up period of 954 days after HSCT, the estimated 3‐year overall survival was 85.7% (95% confidence interval, 33.4–97.9%) with no non‐relapse mortality. Five patients relapsed after RIC‐HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft‐versus‐lymphoma effect and ‘down‐staging’ effect from advanced stage to early stage by HSCT improve the prognosis of advanced‐stage MF/SS. These results suggest that RIC‐HSCT is an effective treatment for advanced MF/SS. Copyright © 2014 John Wiley & Sons, Ltd.

show abstract

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

Cited by 73 publications

References 27 publications

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Practical Management of CD30+ Lymphoproliferative Disorders

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

Contact Info

Product

Resources

About

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

Cited by 73 publications

References 27 publications

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 – mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 – mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Practical Management of CD30+ Lymphoproliferative Disorders

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

Contact Info

Product

Resources

About

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission

Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 ^– mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission